Abstract
B-cell lymphoma has a poor prognosis due to difficulties in early diagnosis and the negative effects of systemic chemotherapy. Therefore, there is an urgent need to develop highly accurate and effective theranostic strategies for B-cell lymphoma. In this study, we designed a poly (lactic-co-glycolic acid) (PLGA)-based theranostic nanoplatform (denoted as TscNPs) to achieve ultrasound (US)/magnetic resonance (MR) bimodal imaging-guided photothermal (PTT)/chemo synergistic therapy of B-cell lymphoma. The nanoplatform was conjugated with a CD20 monoclonal antibody specifically targeting B-cell lymphoma to promote tumor accumulation. Encapsulated superparamagnetic iron oxide nanoparticles (SPIONs) as photothermal and MR imaging agents enabled thermal ablation of tumors and imaging-guided tumor therapy. When exposed to near-infrared (NIR) laser, TscNPs generate heat that induces optical droplet vaporization (ODV) of perfluoropentane (PFP), which transforms into microbubbles. This process not only enhanced ultrasound imaging, but also facilitated the release of celastrol (CST) from the nanoplatform, ultimately achieving a PTT/chemo synergistic therapy effect. In the tumor-bearing nude mice model, TscNPs were effectively accumulated in the tumor region. Furthermore, the combined treatment mode of TscNPs and NIR laser irradiation demonstrated a tumor inhibition rate of approximately 96.57%, which was significantly superior to the rates observed with PTT or chemotherapy alone. These results suggest that the multifunctional theranostic nanoplatform represents a promising new strategy for the therapy of B-cell lymphoma.
Overview
- The study aims to develop a highly accurate and effective theranostic strategy for B-cell lymphoma using a PLGA-based nanoplatform. The nanoplatform is conjugated with a CD20 monoclonal antibody and encapsulates SPIONs as photothermal and MR imaging agents. When exposed to NIR laser, TscNPs generate heat that induces ODV of PFP, facilitating the release of CST and achieving a PTT/chemo synergistic therapy effect. The study uses a tumor-bearing nude mice model to evaluate the efficacy of the combined treatment mode of TscNPs and NIR laser irradiation. The primary objective is to demonstrate the superiority of the combined treatment mode over PTT or chemotherapy alone in inhibiting tumor growth in the nude mice model.
Comparative Analysis & Findings
- The study compares the outcomes observed under different experimental conditions or interventions, including PTT, chemotherapy, and the combined treatment mode of TscNPs and NIR laser irradiation. The results show that the combined treatment mode of TscNPs and NIR laser irradiation demonstrates a tumor inhibition rate of approximately 96.57%, which is significantly superior to the rates observed with PTT or chemotherapy alone. The study identifies the superiority of the combined treatment mode in inhibiting tumor growth in the nude mice model.
Implications and Future Directions
- The study's findings suggest that the multifunctional theranostic nanoplatform represents a promising new strategy for the therapy of B-cell lymphoma. The study identifies the need for further research to optimize the nanoplatform's design and improve its therapeutic efficacy. The study also suggests the potential for the theranostic nanoplatform to be used in clinical settings for the treatment of B-cell lymphoma. Future research directions could include the development of a humanized version of the nanoplatform and the evaluation of its safety and efficacy in clinical trials.